BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 30.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 243,468 shares of the company’s stock after purchasing an additional 56,113 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.10% of BioNTech worth $22,170,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BNTX. Bank of New York Mellon Corp increased its holdings in shares of BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock valued at $63,593,000 after purchasing an additional 694,691 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in BioNTech during the fourth quarter worth $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company’s stock worth $57,191,000 after acquiring an additional 433,388 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in BioNTech during the fourth quarter worth $14,091,000. Finally, Braidwell LP increased its stake in BioNTech by 25.1% during the fourth quarter. Braidwell LP now owns 309,865 shares of the company’s stock worth $35,309,000 after acquiring an additional 62,115 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on BNTX shares. Bank of America raised their target price on BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Citigroup reissued a “buy” rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They set a “neutral” rating and a $110.00 target price for the company. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th. Finally, JPMorgan Chase & Co. cut their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research note on Thursday, May 22nd. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $135.80.

BioNTech Trading Down 0.5%

BNTX opened at $110.77 on Friday. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $131.49. The business has a fifty day simple moving average of $109.81 and a 200-day simple moving average of $105.64. The firm has a market cap of $26.63 billion, a P/E ratio of -69.23 and a beta of 1.23. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter last year, the business posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.